Background: Animal models and human studies have identified the potential of modafinil as a cognitive enhancing agent, independent of its effects on promoting wakefulness in sleep-deprived samples. Given that single-dose applications of other putative memory enhancers (eg, D-cycloserine, yohimbine, and methylene blue) have shown success in enhancing clinical outcomes for anxiety-related disorders, we conducted a meta-analytic review examining the potential for single-dose effects for modafinil on cognitive functioning in non-sleep-deprived adults.
Methods: A total of 19 placebo-controlled trials that examined the effects of single-dose modafinil versus placebo on the cognitive domains of attention, executive functioning, memory, or processing speed were identified, allowing for the calculation of 67 cognitive domain-specific effect sizes.
Results: The overall positive effect of modafinil over placebo across all cognitive domains was small and significant (g = 0.10; 95% confidence interval, 0.05-0.15; P < 0.001). No significant differences between cognitive domains were found. Likewise, no significant moderation was found for modafinil dose (100 mg vs 200 mg) or for the populations studied (psychiatric vs nonpsychiatric).
Conclusions: In conclusion, the available evidence indicates only limited potential for modafinil to act as a cognitive enhancer outside sleep-deprived populations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/JCP.0000000000001085 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of oral modafinil on accelerating consciousness recovery in adult patients with moderate to severe acute traumatic brain injury admitted to intensive care unit: a randomized double-blind clinical trial.
Neurosurg Rev
December 2024
Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Chamran Blvd, Shiraz, 7194815711, Iran.
Background: Traumatic Brain Injury (TBI) is a leading cause of hospitalization and disability in young and middle-aged adults. This study aims to survey the efficacy of oral modafinil, a low-side-effect central nervous system stimulant, in the enhancement of consciousness recovery in moderate to severe TBI patients in the ICUs of a referral trauma center.
Materials And Methods: All ICU patients meeting inclusion criteria between April 2021 and April 2023 were screened.
Modulation of cerebellar-cortical connectivity induced by modafinil and its relationship with receptor and transporter expression.
Biol Psychiatry Cogn Neurosci Neuroimaging
November 2024
Department of Neuroscience, Imaging, and Clinical Sciences, University "G. d'Annunzio" of Chieti-Pescara, Italy; Institute for Advanced Biomedical Technologies (ITAB), "G. d'Annunzio" University, Chieti-Pescara, Italy; Molecular Neurology Unit, Center for Advanced Studies and Technology (CAST), University "G. d'Annunzio" of Chieti-Pescara, Italy. Electronic address:
Article Synopsis
- - Modafinil is used to treat narcolepsy and as a cognitive enhancer, impacting the connectivity of brain networks related to attention and executive function, with less known about its effects on subcortical areas.
- - In a study with 50 participants, researchers measured resting-state fMRI connectivity before and after a single dose of modafinil or a placebo, focusing on cerebellar-neocortical relationships and neurotransmitter receptor expression.
- - Results showed that modafinil enhanced connectivity in specific cerebellar regions (Crus I and Vermis IX) with prefrontal areas and other brain regions, linking these changes to the presence of dopaminergic and histaminergic receptors.
Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the FAERS database.
Front Pharmacol
November 2024
Department of Pharmacology, University of the Basque Country UPV/EHU, Leioa, Spain.
Article Synopsis
- The study investigates the safety of various medications for narcolepsy, a lifelong neurological disorder, using five years of data from the FDA Adverse Event Reporting System (FAERS) to analyze pharmacological treatments like pitolisant, sodium oxybate, solriamfetol, and modafinil.
- Data analysis revealed significant signals for adverse drug events (ADEs), especially psychiatric and nervous system-related issues, with sodium oxybate raising concerns about suicidal thoughts and respiratory problems, while other medications highlighted issues like drug inefficacy and pregnancy-related risks.
- Overall, findings suggest that adverse reactions align with existing product warnings, emphasizing the need for careful management and monitoring of narcolepsy treatments.
Development and Validation of an Analytical Method to Identify and Quantitate Novel Modafinil Analogs in Products Marketed as Dietary Supplements.
J Diet Suppl
October 2024
Kansas City Human and Animal Food Laboratory, Lenexa, KS, USA.
Modafinil (brand name Provigil®) is a Schedule IV (U.S.) drug used for the treatment of narcolepsy and sleep disorders.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!